Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney)

Posted On 2021-07-06 17:55:01


This series on “Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney)” is edited by
- Mieke Van Hemelrijck, Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK; and
- Netty Kinsella, The Royal Marsden Hospital, London, UK; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK.

Better health awareness, access to healthcare and an improvement in diagnostic tests has led to a significant increase in the early detection and diagnosis of localised urological cancers. Expectant management or active surveillance (AS) is used in localised urological cancers and defined as the initial monitoring of tumour size and or grade, with delayed intervention only in tumours demonstrating clinical progression.

Editorial on Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney)
Expectant management in genitourinary malignancies (prostate, bladder, kidney)
Mieke Van Hemelrijck, Netty Kinsella

Original Article on Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney)
Using the Movember Foundation’s GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function—a retrospective study in low-risk prostate cancer patients
R. Trafford Crump, Sebastiaan Remmers, Mieke Van Hemelrijck, Jozien Helleman, Daan Nieboer, Monique J. Roobol, Lionne D. F. Venderbos, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium

Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
Kerri Beckmann, Declan Cahill, Christian Brown, Mieke Van Hemelrijck, Netty Kinsella

Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer—a systematic review
Arvind Nayak, Joanne Cresswell, Paramananthan Mariappan

Endoscopic surveillance for bladder cancer: a systematic review of contemporary worldwide practices
Beth Russell, Pinky Kotecha, Ramesh Thurairaja, Rajesh Nair, Sachin Malde, Pardeep Kumar, Muhammad Shamim Khan

Review Article on Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney)
Surveillance for low-risk kidney cancer: a narrative review of contemporary worldwide practices
Helen Wei Cui, Mark Edward Sullivan

Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?
Nada Humayun-Zakaria, Douglas G. Ward, Roland Arnold, Richard T. Bryan

Active surveillance for prostate cancer
Daniela K. Shill, Monique J. Roobol, Behfar Ehdaie, Andrew J. Vickers, Sigrid V. Carlsson

Editorial Commentary on Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney)
The need for research methodology to improve acceptability of long-term surveillance for cancer
Netty Kinsella, Mieke Van Hemelrijck

Factors that influence patients’ views on treatment decision-making in localised kidney cancer
Katharina Beyer, Ravi Barod, David Nicol, Muddassar Hussain, Mieke Van Hemelrijck, Netty Kinsella

Active surveillance for prostate cancer—will the discoveries of the last 5 years change the future?
Monique J. Roobol

The need for core outcome sets in urological cancer research
Steven MacLennan, Paula R. Williamson

Disclosure:
The series “Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney) ” was commissioned by the editorial office, Translational Andrology and Urology without any sponsorship or funding. Mieke Van Hemelrijck and Netty Kinsella serve as the unpaid guest editors for the special series.